Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI2070 in moderate to severe Crohn's Disease
NCT01714726Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2013
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of brazikumab in Crohn's disease, sponsored by AstraZeneca. Started Feb 2013; status: completed.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01714726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01714726.